HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Tobacco Bill Advocates Extended Use, New Claims For OTC NRTs

This article was originally published in The Tan Sheet

Executive Summary

FDA is directed to consider approving extended use of OTC nicotine replacement products in legislation introduced by Sen. Mike DeWine (R-Ohio) and Edward Kennedy (D-Mass.) May 20

You may also be interested in...



Tobacco bill passes Senate

Branded and generic nicotine replacement therapy products may get quicker routes to market under an amendment to the American Jobs Creation Act of 2004 (HR 4250), which passed the Senate July 15. The amendment, introduced by Sen. Mike DeWine (R-Ohio), would allow FDA regulation of tobacco products and provide a buyout for tobacco farmers. For NRT marketers, the provision advocates the use of time-and-extent applications and other FDA fast-tracking of smoking cessation products, reflecting DeWine's earlier bill (1"The Tan Sheet" May 24, 2004, p. 9)...

FDA Tobacco Oversight Legislation Encounters Setback In Senate

Sen. Mike DeWine (R-Ohio) remains hopeful that compromise legislation giving FDA oversight of tobacco products can be reached before year-end after talks broke down in the Senate Health, Education, Labor & Pensions Committee Oct. 1

FDA Tobacco Regulation Resurfaces As Senate HELP Considers Bill

The definition of FDA-regulated tobacco products in legislation under consideration by the Senate Health, Education, Labor & Pensions Committee excludes "conventional foods.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel